Epistem CEO: Indian TB deal first among many for Genedrive
This article was originally published in Clinica
Epistem last week announced a partnership with biotech firm Xcelris Laboratories to evaluate the Genedrive system – the UK company's point-of-need molecular diagnostics platform – for the early detection of tuberculosis (TB) in India. However, this deal is just the tip of the iceberg. Having spent four to five years developing the technology, Epistem has dedicated the last six months to ramping up production of the handheld analysers and building up the assay processes to support other deals – similar to the one it has with Xcelris – which it has lined up for Genedrive, according to Epistem CEO Matthew Walls.